Search the Newsreel

Is Bionano Genomics Inc (BNGO) Undervalued After Q2 Earnings? EPS: -$7.4M, Revenue: $8.2M, GF Score: 64/100

Earnings call transcript: Bionano Genomics tops Q2 revenue view, shares edge up

Bionano Genomics (NASDAQ: BNGO) grows revenue amid going concern warning

Bionano Genomics presenta sus previsiones de ingresos para el tercer trimestre y el ejercicio 2026

Bionano Genomics, Inc. Q2 2026: Revenue $8.17M, EPS $(0.64) — 10-Q Summary

Bionano Genomics, Inc. reported its Q2 2026 financial results, showing a 21% increase in revenue to $8.17M, up from $6.73M in Q2 2025. Despite this growth, the company recorded a net loss of $7.42M, though the diluted EPS improved significantly from $(1.99) to $(0.64) …

Bionano Reports Second Quarter 2026 Results and Provides a Business Update

Bionano has reported its second-quarter 2026 financial results, which include updates on its operational performance and strategic initiatives. The company also provided a comprehensive business update detailing its progress and future outlook.

BioNTech SE (BNTX) Stock Analysis: Navigating a Potential 28.66% Upside Amidst Volatility

BioNTech SE (BNTX) is a biotechnology company facing financial challenges with negative profitability metrics and significant revenue decline, despite its strong pipeline in oncology and infectious diseases. Analysts, however, see a potential upside of 28.66% with an average target price of $120.52, supported by …

Bionano Genomics (BNGO) Earnings Date and Reports 2026

Why Is Albion Resources (ASX:ALB) Drawing Market Attention?

BioNTech (BNTX) Cuts 2026 Guidance On An Undervalued Story Or Fair Warning

Bionano Genomics Inc (BNGO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bionano Genomics | 8-K: Current report

This article is a current report (8-K filing) from Bionano Genomics. It provides links to two separate documents for more details. The content explicitly states that it is for informational and educational purposes only and does not constitute investment advice.

BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for BioNexus Gene Lab Corp (BGLC), detailing estimated future EPS and revenue growth. It includes current stock information, such as the market capitalization and recent price movements, along with a list of peer companies for comparison. The content …

Bank of New York Mellon Corp Trims Stock Position in BioNTech SE Sponsored ADR $BNTX

Bank of New York Mellon Corp significantly reduced its stake in BioNTech SE by 64.6% in the first quarter, selling over 73,000 shares but still retaining shares worth approximately $3.6 million. Despite a reported quarterly loss, BioNTech outperformed EPS estimates, although revenue missed expectations …

Noticias de acciones de Bionano Genomics Inc (BNGO)

BioNano Genomics Inc (0A4K) Q1 2026 Earnings Report - Results, Call & Slides

BioNano Genomics Inc. (0A4K) reported its Q1 2026 earnings, beating analyst expectations with an EPS of -$0.76 against a consensus of -$0.88 and revenue of $6.69M, surpassing the expected $6.57M. The company highlighted positive operational developments including record flow cell sales, strong consumables growth, …

Beta Bionics (NASDAQ:BBNX) Shares Up 13.7% - Should You Buy?

Beta Bionics (NASDAQ:BBNX) saw its shares surge by 13.7% to $16.05, trading above its 50-day and 200-day moving averages, though its high beta of 3.13 indicates significant volatility. Analysts hold a "Moderate Buy" consensus with a $20.10 price target, despite one firm issuing a …

BioNexus Gene Lab files initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd

BioNexus Gene Lab has filed an initial beneficial ownership statement (Form 3) indicating that Fidelion Diagnostics Pte. Ltd. beneficially owns 392,329 common shares, classifying it as a greater-than-5% holder. This filing, signed by Ling Xiao, notes the ownership as of November 28, 2025, with …

BioNTech (BNTX) Brings In New CEO As Europe Clears Updated COVID 19 Shot

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioNTech (NasdaqGS:BNTX) named Dr. Guido Oelkers as incoming CEO, marking a major leadership transition …

Bionano Genomics, Inc. expected to post a loss of 68 cents a share - Earnings Preview

Bionano Genomics, Inc. is projected to report a loss of 68 cents per share, according to this earnings preview. The article, provided by Refinitiv and featured on TradingView News, offers a brief overview of the upcoming financial expectation for BNGO. Readers can access the …

Fidelion Diagnostics reports 392,329 BioNexus Gene Lab Corp (NASDAQ: BGLC) shares

Fidelion Diagnostics PTE. LTD. has reported direct ownership of 392,329 shares of BioNexus Gene Lab Corp (NASDAQ: BGLC) common stock, identifying itself as a greater than 5% holder. This Form 3 filing is an initial statement of holdings and does not indicate any recent …

BioNexus Gene Lab Corp (BGLC) Stock News Today

Bionano Genomics Inc (BNGO) Stock News Today

This article provides current stock information for Bionano Genomics Inc (BNGO), showing a recent increase of 5.45%. It indicates that more news regarding BNGO's stock, earnings, and analyst ratings will be available soon. The page serves as a hub for financial data and updates …

BioNTech SE (NASDAQ:BNTX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

BioNTech SE's latest quarterly report has led to a darkening of analyst consensus forecasts, with analysts cutting revenue predictions by 19% and earnings per share forecasts by 22%. Despite these downward revisions, the consensus price target remains stable at US$139, suggesting that the market …

BioNTech SE (NASDAQ:BNTX) Just Reported And Analysts Have Been Cutting Their Estimates

BioNTech SE recently reported disappointing quarterly results, with revenues missing forecasts and losses exceeding expectations. Consequently, analysts have significantly cut next year's revenue estimates and increased loss per share forecasts, though the average price target remained unchanged. The company's revenue is expected to continue …

BNGO Q2'26 Earnings: EPS estimate is (0.67) USD

Bionano Genomics, Inc. (BNGO) is scheduled to release its Q2'26 financial results on August 10, after market close. The company is expected to report an estimated revenue of $7.55 million and an estimated earnings per share (EPS) of ($0.67) for the quarter. This article …

BioNTech SE Sponsored ADR Revenue Breakdown – BSESOF:22UA

This article provides a revenue breakdown for BioNTech SE Sponsored ADR (BSESOF:22UA). It highlights that the company generated 2.87 billion EUR last year, with Immunotherapy Technologies being the top-performing segment, contributing 2.76 billion EUR. The United States was the largest regional contributor, accounting for …

Downgrade: Here's How Analysts See BioNTech SE (NASDAQ:BNTX) Performing In The Near Term

BioNTech SE (NASDAQ:BNTX) recently received significant downgrades from analysts, with cuts to both revenue and earnings per share forecasts for 2026. Analysts now predict a 30% decline in sales to €1.9 billion and increased losses of €5.45 per share, indicating a negative shift in …

Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX

Lazard Asset Management LLC has acquired a new stake of 71,905 shares in Beta Bionics (NASDAQ:BBNX), valued at approximately $720,000, representing 0.16% ownership. Other institutional investors also established or increased positions in the company. Beta Bionics shares recently traded down 4.5% at $13.91, with …

Bionano Genomics (BNGO) grants 5,000 options to officer

Bionano Genomics (BNGO) reported that its Principal Accounting Officer, Mark Adamchak, received a grant of 5,000 stock options. These options have an exercise price of $1.12 per share, vest 50% on the first and second anniversaries of the vesting commencement date, and expire on …

Bionano Genomics (NASDAQ: BNGO) awards 15,000 options to its general counsel

Bionano Genomics (NASDAQ: BNGO) has granted 15,000 stock options to its General Counsel, Jonathan V. Dixon, on August 3, 2026. The options have an exercise price of $1.12 per share and will expire on August 2, 2036. These options vest 50% on each of …

Bionano Genomics, Inc. (BNGO) CSO lists 54,000-share stock option position

Bionano Genomics, Inc. (BNGO) Chief Scientific Officer Hastie Alex Reid has reported a stock option to buy 54,000 shares of common stock at an exercise price of $1.12 per share, expiring on August 2, 2036. The vesting schedule includes 25% of the shares becoming …

BioNTech SE (BNTX) Misses Q2 EPS by 18c

BioNTech SE (BNTX) reported its Q2 earnings, missing analyst estimates for both EPS and revenue. The company posted a Q2 EPS of (EUR2.22), which was EUR0.18 worse than the estimated (EUR2.04), and revenue came in at EUR105.6 million, significantly below the consensus estimate of …

Control Bionics Wins Strong Shareholder Backing for Major Capital Raisings

BioNTech se quedan por debajo de 0.18€ las previsiones de BPA en el segundo trimestre del año

Earnings Preview: BNGO to Report Financial Results Post-market on August 10

Bionano Genomics (BNGO) is scheduled to report its financial results on August 10 after the market closes. Analysts are anticipating a loss of $0.06 per share on revenue of $10.14 million for the quarter. This release will provide investors with an update on the …